JDRF Study Results Show Continuous Glucose Monitoring Provides Significant Benefits...

JDRF Study Results Show Continuous Glucose Monitoring Provides Significant Benefits in Management of Type 1 Diabetes

ROME--(Business Wire)--
New study data presented by the Juvenile Diabetes Research
Foundation (JDRF) today at the 44th annual meeting of the European
Association for the Study of Diabetes (EASD), showed the use of
Continuous Glucose Monitoring (CGM) to be effective in the management
of Type 1 Diabetes.

The JDRF initiated the study to help increase access to and
reimbursement of this new technology, which has been heralded as one
of the most significant advancements in diabetes self-management in
the past decade. The 322 person, six-month, multi-center randomized
trial included both pediatric and adult patients who used either
insulin pumps or multiple daily injections to manage their diabetes.
The study was conducted in the United States, and utilized all three
commercially-available CGM systems, including the Seven(R) System -
developed by San Diego based DexCom(TM), Inc.

Highlights of the study results include:

-- Patients 25 years of age or older who used CGM showed
significant improvement in glucose control as measured by
HbA1c.

-- Most importantly, this improvement in control was observed
without an increase in hypoglycemia (low blood sugar), which
is a common concern in intensively managed patients trying to
achieve improved glucose control.

-- In all ages, patients who used CGM at least six days a week
had substantially improved HbA1c levels.

"As the only company with an FDA approved seven-day sensor, we
believe the Seven System allows patients the unique opportunity to
achieve better glucose control. We applaud the JDRF for supporting
outcomes studies in the area of CGM technology and are extremely
encouraged by their results, which independently validate the
effectiveness of this therapy." said Terrance H. Gregg, DexCom's
President and CEO. "We are particularly excited that the positive
results of this study are expected to continue to build momentum with
the payer community, leading to greater patient access to the
technology."

"The findings from this study demonstrate continuous glucose
monitoring devices, such as DexCom's Seven System can be safely and
effectively used by patients," said Steve Edelman M.D., Professor of
Medicine, University of California, San Diego, and Founder of Taking
Control of Your Diabetes, a patient advocacy organization. "As an
Endocrinologist and CGM user myself, I believe this technology will
rapidly become the standard of care for diabetes management and can
truly change the lives of people with diabetes."

DexCom, Inc.(NASDAQ:DXCM), headquartered in San Diego, California,
is developing and marketing continuous glucose monitoring systems for
people with diabetes.

DexCom, Inc.
Steven R. Pacelli
Senior Vice President of Corporate Affairs
858-200-0200
spacelli@dexcom.com

Copyright Business Wire 2008